Federal grant · project grant (b)

Cognition Therapeutics, Inc.

Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months

Committed

$64.2 Million

Paid out
$45.2M
70%
Committed, not yet paid
$19.1M
30%

How to read these numbers

One award, start to finish: Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed vs. ceiling: Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
Paid out: The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
The ledger: Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
The money bar: One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then .

Source

This award on USAspending.gov ↗